
Claims

1. A compound of the formula:



,

where R_1 and R_2 are each H,
or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising:
a compound according to claim 1 formulated with a pharmaceutically acceptable carrier.

3. The pharmaceutical composition according to claim 2, wherein the pharmaceutically acceptable carrier comprises one or more agents selected from the group consisting of lipids, interbilayer crosslinked multilamellar vesicles, biodegradeable poly(D,L-lactic-co-glycolic acid) [PLGA]-based or poly anhydride-based nanoparticles or microparticles, and nanoporous particle-supported lipid bilayers.

4. A composition comprising:

a compound according to claim 1, and one or more antigens selected for purposes of inducing an immune response against the antigen(s) when the composition is to be administered to an individual.

5. Use of a compound according to claim 1 in the manufacture of a medicament for inducing stimulator of interferon genes protein (STING)-dependent type I interferon production in an individual in need thereof, wherein said compound is to be administered to said individual in an amount sufficient to induce STING-dependent type I interferon production.

6. The use according to claim 5, wherein the compound is to be administered directly into a tumor mass.

7. Use of a compound according to claim 1 in the manufacture of a medicament for treating cancer in an individual in need thereof.

8. The use according to claim 7, wherein the use is to be in combination with a CTLA-4 antagonist, a PD-1 pathway antagonist, a TLR agonist, or one or more therapeutic antibodies.

9. The use according to claim 8, wherein the use is to be in combination with a CTLA-4 pathway antagonist selected from the group of Ipilimumab and tremelimumab.

10. The use according to claim 8, wherein the use is in combination with a PD-1 pathway antagonist selected from the group consisting of MK-3475, CT-011, AMP-224 and MDX-1106.

11. The use according to claim 9, wherein the use is in combination with a PD-1 pathway antagonist selected from the group consisting of MK-3475, CT-011, AMP-224 and MDX-1106.

12. The use according to any one of claims 8 – 11, wherein the use is to comprise separate administration of the compound according to claim 1 and one or both of a CTLA-4 pathway antagonist and a PD-1 pathway antagonist.

13. The use according to claim 12, wherein the separate administration is to comprise administration at different times.

14. The use according to claim 12, wherein the separate administration is to comprise administration by different routes of administration.

15. The use according to any one of claims 8 – 11, wherein the cancer is selected from the group consisting of a colorectal cancer, an aero-digestive squamous cancer, a lung cancer, a brain cancer, a liver cancer, a stomach cancer, a sarcoma, a leukemia, a lymphoma, a multiple myeloma, an ovarian cancer, a uterine cancer, a breast cancer, a melanoma, a prostate cancer, a pancreatic carcinoma, and a renal carcinoma.